STOCK TITAN

Autolus Therapeutics (AUTL) director details ADS option holdings on Form 3

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Autolus Therapeutics plc director Rao Madduri Ravin filed an initial Form 3 reporting existing stock option holdings linked to American Depositary Shares. He holds three direct option positions, each covering 80,000 ADS, with exercise prices of $5.68, $3.48, and $2.32 per share and expirations in 2034 and 2035. One option is fully vested and exercisable, while the others vest in equal monthly installments starting on May 1, 2024 and July 26, 2025, indicating a staged compensation structure rather than recent market trades.

Positive

  • None.

Negative

  • None.
Insider Rao Madduri Ravin
Role Director
Type Security Shares Price Value
holding Share Option (right to buy) -- -- --
holding Share Option (right to buy) -- -- --
holding Share Option (right to buy) -- -- --
Holdings After Transaction: Share Option (right to buy) — 80,000 shares (Direct)
Footnotes (1)
  1. This option vested or vests in 36 equal monthly installments commencing on May 1, 2024. Fully vested and exercisable. This option vested or vests in twelve equal monthly installments commencing on July 26, 2025.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Rao Madduri Ravin

(Last)(First)(Middle)
C/O AUTOLUS THERAPEUTICS PLC
THE MEDIAWORKS, 191 WOOD LN, WHITE CITY

(Street)
LONDONW12 7FP

(City)(State)(Zip)

UNITED STATES

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026
3. Issuer Name and Ticker or Trading Symbol
Autolus Therapeutics plc [ AUTL ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Share Option (right to buy) (1)04/01/2034American Depositary Shares80,000$5.68D
Share Option (right to buy) (2)06/28/2034American Depositary Shares80,000$3.48D
Share Option (right to buy) (3)06/26/2035American Depositary Shares80,000$2.32D
Explanation of Responses:
1. This option vested or vests in 36 equal monthly installments commencing on May 1, 2024.
2. Fully vested and exercisable.
3. This option vested or vests in twelve equal monthly installments commencing on July 26, 2025.
/s/ Michael Bonney03/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Autolus (AUTL) Form 3 filing by Rao Madduri Ravin report?

The Form 3 reports director Rao Madduri Ravin’s existing stock option holdings in Autolus Therapeutics plc. It lists three direct options over American Depositary Shares, detailing exercise prices, expiration dates, and vesting schedules, establishing his initial derivative ownership position as a company insider.

How many Autolus (AUTL) ADS are covered by Rao Madduri Ravin’s options?

Rao Madduri Ravin holds three option positions, each linked to 80,000 American Depositary Shares. These options have exercise prices of $5.68, $3.48, and $2.32 per share, providing significant potential equity exposure if fully exercised over the option terms.

What are the exercise prices and expirations of Rao Madduri Ravin’s Autolus (AUTL) options?

His options have exercise prices of $5.68, $3.48, and $2.32 per ADS. The expiration dates are April 1, 2034, June 28, 2034, and June 26, 2035, providing long-dated exposure aligned with Autolus’s long-term performance.

How do Rao Madduri Ravin’s Autolus (AUTL) options vest over time?

One option is fully vested and exercisable, while another vests in 36 equal monthly installments starting May 1, 2024. A third option vests in twelve equal monthly installments starting July 26, 2025, creating a staggered vesting schedule tied to ongoing service.

Does the Autolus (AUTL) Form 3 show any recent insider buying or selling?

The Form 3 reflects existing holdings and shows no explicit buy or sell transactions. The entries are classified as holdings of stock options, indicating derivative positions rather than new open-market purchases or sales of Autolus American Depositary Shares.